Heather Shane leads the CARB-X accelerator at CLSI, providing non-dilutive funding, entrepreneurial support and subject matter expertise to start-ups with innovative antibiotic product candidates. CARB-X, an international consortium comprised of leaders in industry, philanthropy, government and academia, is the world’s largest public-private partnership focused on combating antimicrobial resistance. Prior to joining CLSI, Heather served as Vice President & Assistant General Counsel at Theravance Biopharma (TBPH), a Bay Area biopharmaceutical company with a deep and diverse pipeline of product candidates, a commercial-stage antibiotic and financial assets. At TBPH, Heather handled a broad range of corporate, financing, partnering and operational matters, and honed her legal and business skills in the drug discovery and clinical development process, product commercialization and the regulatory and compliance regimes governing these activities. Heather joined TBPH in connection with its 2014 spin-off from and Theravance (now known as Innoviva), where she also served as Vice President & Assistant General Counsel. Before joining Theravance in 2005, Heather was a corporate associate with Gunderson Dettmer Stough Villeneuve & Hachigian where she represented start-ups, venture capital and public company clients in a variety of transactions.